We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Pressing ahead with its "mosaic" HIV vaccine, which aims to guard against viral subtypes worldwide, Johnson & Johnson reports that its regimen elicited immune responses that lasted one year after vaccination in phase 1/2a study participants.